May 21, 2026—Finland’s Grundium, backed by U.S.-based health care private equity firm EW Healthcare Partners, has acquired Visiopharm, of Denmark. The acquisition is part of Grundium’s effort to build a broader digital and computational pathology platform.
By combining Grundium’s scanner portfolio with Visiopharm’s AI-driven software, the platform supports a range of use cases, from individual laboratory workflows to enterprise-scale deployments, biomarker development, translational research, clinical studies, and companion diagnostic programs.
“Grundium and Visiopharm bring together highly complementary capabilities,” Michael Grunkin, CEO of Visiopharm, said in a joint press statement. “This combination allows us to connect biomarker analysis, imaging, and quality management in new ways, while continuing to support the software and workflows our customers rely on today. Together, we are better positioned to support the next phase of precision diagnostics.”
Grundium’s scanners and Visiopharm’s software will continue to be supported and available independently. Customers can keep their current solutions or combine capabilities as their needs evolve.